Lundbeck drug wins general reimbursement
![Foto: Lundbeck, PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article5791633.ece/ALTERNATES/schema-16_9/Lundbeck_Inc.jpg)
Danish patients receiving treatment with schizophrenia drug Abilify Maintena from Lundbeck and its Japan-based partner Otsuka are sure to have part of their medicine purchases reimbursed.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
IRF unimpressed by Lundbeck and Novo
For abonnenter
Lundbeck launches alcohol pill in Denmark
For abonnenter
Lundbeck’s alcohol pill hits speed bump
For abonnenter